Cite
Gerhardt K, Jentzsch M, Georgi T, et al. Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases. Front Oncol. 2021;11:737645doi: 10.3389/fonc.2021.737645.
Gerhardt, K., Jentzsch, M., Georgi, T., Sretenović, A., Cross, M., Bach, E., Monecke, A., Leiblein, S., Hoffmann, S., Todorović, M., Bila, J., Sabri, O., Schwind, S., Franke, G. N., Platzbecker, U., & Vučinić, V. (2021). Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases. Frontiers in oncology, 11737645. https://doi.org/10.3389/fonc.2021.737645
Gerhardt, Kristin, et al. "Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases." Frontiers in oncology vol. 11 (2021): 737645. doi: https://doi.org/10.3389/fonc.2021.737645
Gerhardt K, Jentzsch M, Georgi T, Sretenović A, Cross M, Bach E, Monecke A, Leiblein S, Hoffmann S, Todorović M, Bila J, Sabri O, Schwind S, Franke GN, Platzbecker U, Vučinić V. Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases. Front Oncol. 2021 Sep 16;11:737645. doi: 10.3389/fonc.2021.737645. eCollection 2021. PMID: 34604075; PMCID: PMC8481921.
Copy
Download .nbib